IQ Consortium

Organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology.

What is IQ?

The IQ Consortium is a not-for-profit organization of pharmaceutical and biotechnology companies with the mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community.

 

IQ News

IQ 2024 Distinguished Service Awardees Announced

The IQ Distinguished Service Award recognizes outstanding individuals who have demonstrated enduring and impactful commitment to IQ’s mission. These individuals have made significant contributions to advancing IQ initiatives and have been proud ambassadors of the consortium. This is the inaugural year for this award, and we are delighted to honor our first class of awardees: Timothy Curran, Olivier Dirat, Timothy Hart, Sebastian Haertter, James Mann, Thomas Monticello, David Tan, and Jean-Pierre Valentin.

IQ Public Call

IQ DILI Initiative NONCLINICAL TRANSLATION Working Group – Nonmember Solicitation

Responses Due 22-Sep-2025

Traditional risk assessment approaches for predicting and understanding mechanisms of drug-induced liver injury (DILI) have largely focused on small molecule therapeutics. However, as the drug landscape continues to evolve, small molecules now represent just one of many therapeutic modalities in portfolios across industry. One primary area of focus for the Nonclinical Translation working group is oligonucleotide therapeutics, an emerging class of drugs designed to address targets and pathways previously considered “undruggable” by traditional small molecules. Although significant progress has been made in evaluating the nonclinical safety of oligonucleotide therapeutics, hepatotoxicity remains a safety concern as the liver represents a major organ of uptake and exposure for some oligonucleotides. Their distinct mechanism of action and metabolic pathways present challenges, including hybridization-dependent and -independent off-target effects, exaggerated on-target pharmacology, immune-mediated responses to foreign nucleotides and differences in cellular processing; all of which can potentially contribute to liver injury. These complexities underscore the need to re-evaluate the relevance and effectiveness of traditional nonclinical safety approaches to assess DILI risk for emerging therapeutic modalities.